Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRIUMPH-OUTCOMES

TRIUMPH-OUTCOMES

Retatrutide · Obesity + CVD

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
Obesity + CVD
Official title
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
active not recruiting · 2024-04 → 2029-02
Participants
10000
Registry
NCT06383390

Ongoing outcome trial

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
TRIUMPH-OUTCOMESRetatrutideObesity + CVD
Obesity (BMI ≥27) + ASCVD, with or without T2D
MACE10000active not recruiting2029-02NCT06383390

No results yet; the primary completion date comes from the registry.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRIUMPH-OUTCOMES. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-outcomes/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.